Tr1x
Tr1X is a biotechnology company that specializes in the development of allogeneic engineered regulatory T (Treg) and chimeric antigen receptor Treg (CAR-Treg) cell therapies aimed at treating autoimmune and inflammatory diseases. Tr1X's lead investigational therapy, TRX103, is an allogeneic engineered T cell product derived from CD4+ cells sourced from healthy donors, designed to mimic the function of Type 1 regulatory T (Tr1) cells. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for TRX103, allowing the initiation of clinical trials for treatment-refractory Crohn’s Disease. Additionally, Tr1X has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the TRX103 Phase 1/2a clinical trial for Graft-Versus-Host Disease.
Tech Stack (29 technologies)
Frequently Asked Questions
What technologies does Tr1x use?+
Tr1x uses 29 technologies including Cookiebot, Elementor, jsDelivr.
What industry is Tr1x in?+
Tr1x operates in the Biotechnology industry.
Where is Tr1x based?+
Tr1x is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026